• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Protagonist Therapeutics (PTGX)

Common Shares
Sell: $70.00|Buy: $85.00|Change: 0.97 (1.19%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Itspipeline products include Rusfertide (PTG-300) and JNJ-2113.

Address

7707 Gateway Boulevard
Suite 140
Newark
CA
USA
94560

Telephone

+1 510 4740170

Website

https://www.protagonist-inc.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Protagonist Therapeutics Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
Protagonist Therapeutics Inc Second Quarter Earnings Results for 20262026-08-06T00:00:00
Protagonist Therapeutics Inc Annual General Meeting for 20262026-06-19T10:00:00
Protagonist Therapeutics Inc First Quarter Earnings Results for 20262026-05-05T00:00:00
Protagonist Therapeutics Inc Fourth Quarter Earnings Results for 20252026-02-20T17:30:00
Protagonist Therapeutics Inc Annual Report for 20252026-02-20T00:00:00

Previous key dates

NameKey Date
Protagonist Therapeutics Inc Fourth Quarter Earnings Results for 20252026-02-20T17:30:00
Protagonist Therapeutics Inc Annual Report for 20252026-02-20T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-13T08:15:00
Protagonist at the Citi Global Healthcare Conference2025-12-02T09:00:00
Jefferies Global Healthcare Conference2025-11-19T10:00:00
TD Cowen Immunology & Inflammation Summit2025-11-12T12:30:00
Protagonist Therapeutics Inc Third Quarter Earnings Results for 20252025-11-06T00:00:00
BofA 11th Annual World Medical Innovation Forum2025-09-16T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-09T11:30:00
Citi's 2025 Biopharma Back to School Summit2025-09-03T09:45:00
Protagonist Therapeutics Inc Second Quarter Earnings Results for 20252025-08-06T00:00:00
Oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results2025-06-30T16:30:00
Protagonist Therapeutics Inc Annual General Meeting for 20252025-06-20T10:00:00
Jefferies Global Healthcare Conference 20252025-06-04T13:25:00
Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 20252025-06-02T08:00:00
Protagonist Therapeutics Inc First Quarter Earnings Results for 20252025-05-05T00:00:00
Investor Conference Call2025-03-03T08:30:00
Protagonist Therapeutics Inc Fourth Quarter Earnings Results for 20242025-02-21T17:30:00
Protagonist Therapeutics Inc Annual Report for 20242025-02-21T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.